Nonactivated versus thrombin-activated platelets on wound healing and fibroblast-to-myofibroblast differentiation in vivo and in vitro.

Plast Reconstr Surg

Lausanne and Geneva, Switzerland; Boston, Mass.; and Toronto, Ontario, Canada From the Department of Plastic Surgery, University Hospitals of Lausanne; the Department of Plastic, Reconstructive, and Aesthetic Surgery, University Hospitals of Geneva and Faculty of Medicine, University of Geneva; the Laboratory of Cell Biophysics, Ecole Polytechnique Fédérale de Lausanne; the Tissue Engineering and Wound Healing Laboratory, Brigham and Women's Hospital; and the Laboratory of Tissue Repair and Regeneration, Matrix Dynamics Group, Faculty of Dentistry, University of Toronto.

Published: January 2012

Background: Platelet preparations for tissue healing are usually preactivated before application to deliver concentrated growth factors. In this study, the authors investigated the differences between nonactivated and thrombin-activated platelets in wound healing.

Methods: The healing effects (i.e., wound closure, myofibroblast formation, and angiogenesis) of nonactivated and thrombin-activated platelets were compared in experimental wounds in diabetic (db/db) animals. In vitro, fibroblast phenotype and function were tested in response to platelets and activated platelets. No treatment served as a negative control.

Results: Wounds treated with platelets reached 90 percent closure after 15 days, faster than activated platelets (26 days), and with higher levels of myofibroblasts and angiogenesis. In vitro, platelets enhanced cell migration and induced two-fold higher myofibroblast differentiation and contraction compared with activated platelets.

Conclusions: Platelets stimulate wound healing more efficiently compared with activated platelets by enhancing fibroblast differentiation and contractile function. Similar levels of growth factors may induce different biological effects when delivered "on demand" rather than in an initial bolus.

Download full-text PDF

Source
http://dx.doi.org/10.1097/PRS.0b013e3182362010DOI Listing

Publication Analysis

Top Keywords

thrombin-activated platelets
12
activated platelets
12
platelets
10
platelets wound
8
wound healing
8
growth factors
8
nonactivated thrombin-activated
8
compared activated
8
nonactivated versus
4
versus thrombin-activated
4

Similar Publications

Novel Deep Sea Isoindole Alkaloid FGFC1 Exhibits Its Fibrinolytic Effects by Inhibiting Thrombin-Activatable Fibrinolysis Inhibitor.

Pharmaceuticals (Basel)

October 2024

Department of Marine Bio-Pharmacology, College of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China.

Background: The thrombin-activatable fibrinolysis inhibitor (TAFI) is an important regulator in the balance between blood clot formation (coagulation) and dissolution (fibrinolysis), which is mainly activated by thrombin bonded with thrombomodulin (TM).

Methods: In this study, the investigation focused on the unique target TAFI of fungi fibrinolytic compound 1 (FGFC1), a novel fibrinolytic compound sourced from the deep sea. In this sense, the regulation of TAFI by FGFC1, in comparison to established TAFI inhibitors such as DS-1040 and PCTI in hPPP, was investigated, which was validated through the molecular docking of FGFC1 to TAFI.

View Article and Find Full Text PDF

This research aims to investigate the impact of Didang decoction (DD) on the formation of neutrophil extracellular traps (NETs) and cancer-associated thrombosis in lung cancer. BALB/c nude mice were used to establish xenograft models for inducing deep vein thrombosis. Tumor growth and thrombus length were assessed.

View Article and Find Full Text PDF

Venous thrombosis (VT) is a common vascular disease associated with reduced survival and a high recurrence rate. Previous studies have shown that the accumulation of platelets and neutrophils at sites of endothelial cell activation is a primary event in VT, but a role for platelet αIIbβ3 in the initiation of venous thrombosis has not been established. This task has been complicated by the increased bleeding linked to partial agonism of current αIIbβ3 inhibitory drugs such as tirofiban (Aggrastat ).

View Article and Find Full Text PDF
Article Synopsis
  • - Monoclonal antibodies (mAbs) have been used to study the platelet αIIbβ3 protein, and a new mAb called R21D10 was identified that interferes with protein disulfide isomerase (PDI) binding to activated platelets.
  • - R21D10 not only inhibits PDI binding but also affects fibrinogen and PAC-1 binding, as well as platelet aggregation induced by specific peptides, without impacting the binding of other known mAbs against αIIbβ3.
  • - Structural analysis using cryogenic electron microscopy showed that R21D10 binds to a specific domain on β3 integrin and induces conformational changes in αIIbβ3, suggesting a
View Article and Find Full Text PDF

The purification of a fibrinolytic enzyme from the fruiting bodies of wild-growing medicinal mushroom, Pycnoporus coccineus was achieved through a two-step procedure, resulting in its homogeneity. This purification process yielded a significant 4.13-fold increase in specific activity and an 8.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!